-+ 0.00%
-+ 0.00%
-+ 0.00%
Rein Therapeutics Reports Preliminary 12-Week Blinded Phase 2 RENEW Data For LTI-03 In IPF Patients; Study Achieves 75% Enrollment, With 90 Patients Randomized To Date; On Track To Report Topline Data In 2027
Share
Listen to the news
  • 33% of evaluable patients demonstrated improvement over baseline in forced vital capacity (FVC) at Week 12
  • From baseline, change in FVC ranged from an improvement of 338 ml to a decline of 349 ml at Week 12
  • Low discontinuation rates, and favorable safety and tolerability observed across placebo and treatment groups, with no serious adverse events assessed as related to study treatment
  • Study has achieved 75% enrollment, with 90 patients randomized to date; on track to report topline data in 2027

AUSTIN, Texas, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced preliminary blinded twelve-week observations from the ongoing RENEW Phase 2 trial evaluating its lead drug candidate, LTI-03, in patients with idiopathic pulmonary fibrosis (IPF).

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending